Tauriga Sciences, Inc. (TAUG)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Tauriga Sciences, Inc. (TAUG) trades at $0.00 with AI Score 58/100 (Grade B). Tauriga Sciences, Inc. develops and sells cannabidiol (CBD) infused products, including chewing gum, skincare, and dietary supplements. Market cap: $2,999, Sector: Healthcare.
Price live · AI analysis from Mar 17, 2026Analyst Coverage for TAUG: TAUG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates TAUG against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
TAUG: 1/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Tauriga Sciences, Inc. (TAUG) Healthcare & Pipeline Overview
Tauriga Sciences, Inc. focuses on developing and distributing cannabidiol (CBD) infused products, including Tauri-Gum, skincare, and dietary supplements, through e-commerce and wholesale channels. With a negative profit margin and a small team, the company operates in the competitive specialty drug and CBD market.
What Is the Investment Thesis for TAUG?
Tauriga Sciences operates in the high-growth CBD market, but its negative profit margin of -1271.0% raises concerns about its financial sustainability. A potential growth catalyst is the increasing consumer acceptance of CBD products and expansion into new markets. The company's collaboration with Aegea Biotechnologies for a COVID-19 test could provide a short-term revenue boost, but the long-term impact is uncertain. The company's small size (2 employees) and limited resources pose challenges to scaling operations and competing with larger players. Investors should carefully consider the company's financial position, competitive landscape, and regulatory risks before investing.
Based on FMP financials and quantitative analysis
TAUG Key Highlights
- Market Cap of 3K indicates a micro-cap company with limited liquidity and higher volatility.
- Gross Margin of 43.0% suggests potential profitability in product sales before operating expenses.
- Negative P/E ratio of -0.00 reflects the company's current lack of profitability.
- Profit Margin of -1271.0% indicates significant losses relative to revenue, requiring careful monitoring.
- Beta of -0.73 suggests the stock is less volatile than the market, but may not hold true given the company's OTC status.
Who Are TAUG's Competitors?
TAUG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| ALIM Alimera Sciences, Inc. | $5.54 | -0.18% | $301.29M | 60 |
| EGRX Eagle Pharmaceuticals, Inc. | $0.67 | +0.00% | $8.82M | 60 |
| ADMP Adamis Pharmaceuticals Corporation | $0.78 | +0.85% | $7.25M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are TAUG's Key Strengths?
- CBD-infused product line with Tauri-Gum as a flagship product.
- Distribution network through e-commerce, distributors, and wholesale channels.
- Collaboration agreement with Aegea Biotechnologies for COVID-19 test development.
- Focus on developing innovative CBD products.
What Are TAUG's Weaknesses?
- Negative profit margin and limited financial resources.
- Small team size and limited operational capacity.
- Dependence on the evolving regulatory landscape for CBD products.
- Limited brand recognition compared to larger competitors.
What Could Drive TAUG Stock Higher?
- Increasing consumer acceptance of CBD products could drive demand for Tauriga Sciences' products.
- Potential regulatory changes in the CBD industry could create new opportunities or challenges.
- Expansion of distribution channels and partnerships could increase sales and market reach.
What Are the Key Risks for TAUG?
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Intense competition in the CBD market could limit Tauriga Sciences' ability to gain market share.
- Regulatory uncertainty and potential changes in CBD regulations could negatively impact the company's operations.
- Negative profit margin and limited financial resources pose a significant risk to the company's sustainability.
- Dependence on a small team and limited operational capacity could hinder growth and expansion.
- Fluctuations in raw material prices and supply chain disruptions could impact profitability.
What Are the Growth Opportunities for TAUG?
- Expansion of Product Line: Tauriga Sciences can expand its product line to include new CBD-infused products, such as edibles, beverages, and topical creams. The global CBD market is projected to reach $55.79 billion by 2028, offering significant growth potential. By introducing innovative products, Tauriga Sciences can attract new customers and increase its market share. Timeline: 1-2 years.
- Strategic Partnerships: Collaborating with established retailers and distributors can significantly expand Tauriga Sciences' reach and market penetration. Partnering with major retailers could provide access to a wider customer base and increase brand visibility. The retail CBD market is expected to grow rapidly, driven by increasing consumer demand. Timeline: 6-12 months.
- E-commerce Optimization: Enhancing its e-commerce platform and digital marketing efforts can drive online sales and customer engagement. Investing in SEO, social media marketing, and targeted advertising can attract new customers and increase brand awareness. The online CBD market is experiencing rapid growth, offering significant opportunities for companies with strong e-commerce capabilities. Timeline: Ongoing.
- International Expansion: Expanding into international markets, particularly in Europe and Asia, can unlock new growth opportunities. The European CBD market is projected to grow significantly in the coming years, driven by increasing consumer acceptance and favorable regulations. Tauriga Sciences can partner with local distributors to enter these markets and adapt its products to local preferences. Timeline: 2-3 years.
- Development of Novel Formulations: Investing in research and development to create novel CBD formulations and delivery methods can provide a competitive advantage. Developing proprietary formulations with enhanced bioavailability or targeted effects can differentiate Tauriga Sciences' products from competitors. The market for innovative CBD products is growing rapidly, driven by consumer demand for more effective and convenient solutions. Timeline: 2-5 years.
What Opportunities Does TAUG Have?
- Expansion of product line to include new CBD-infused products.
- Strategic partnerships with established retailers and distributors.
- E-commerce optimization and digital marketing efforts.
- International expansion into new markets.
- Development of novel CBD formulations and delivery methods.
What Threats Does TAUG Face?
- Intense competition from established pharmaceutical companies and CBD brands.
- Regulatory uncertainty and potential changes in CBD regulations.
- Fluctuations in raw material prices and supply chain disruptions.
- Changing consumer preferences and market trends.
What Are TAUG's Competitive Advantages?
- Proprietary CBD formulations (if any).
- Established brand recognition for Tauri-Gum (if any).
- Distribution network through e-commerce and wholesale channels.
- Collaboration agreement with Aegea Biotechnologies for COVID-19 test development.
What Does TAUG Do?
Tauriga Sciences, Inc., founded in 2001 and headquartered in Wappingers Falls, New York, operates within the healthcare sector, specifically in the specialty and generic drug manufacturing industry. The company is engaged in the production and sale of cannabidiol (CBD) infused products. Its primary product is Tauri-Gum, a CBD-infused chewing gum. Additionally, Tauriga Sciences develops and markets a range of other products, including anti-nausea solutions and a variety of CBD-based skincare items such as CBD facemasks, daily moisturizers, anti-wrinkle creams, hand and foot creams with hemp seed oil, massage and body oils, body revive roll-ons, transdermal patches, and body sprays. The company also offers a rainbow deluxe sampler pack, CBD non-GMO dietary supplements, and CBD scented bath bombs. Tauriga Sciences distributes its products through multiple channels, including its e-commerce platform, distributors, and wholesale partners. The company also has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid, multiplexed COVID-19 test.
What Products and Services Does TAUG Offer?
- Produces and sells CBD-infused chewing gum under the Tauri-Gum brand.
- Develops anti-nausea products.
- Offers CBD-based skincare products, including facemasks, moisturizers, and creams.
- Sells CBD non-GMO dietary supplements.
- Markets CBD scented bath bombs.
- Distributes products through e-commerce, distributors, and wholesale channels.
How Does TAUG Make Money?
- Develops and manufactures CBD-infused products.
- Sells products directly to consumers through its e-commerce platform.
- Distributes products through wholesale channels and partnerships with retailers.
- Generates revenue through product sales.
What Industry Does TAUG Operate In?
Tauriga Sciences operates in the specialty and generic drug manufacturing industry, with a focus on CBD-infused products. The CBD market has experienced rapid growth due to increasing consumer awareness and acceptance of CBD's potential health benefits. However, the market is also highly competitive, with numerous companies offering similar products. Regulatory uncertainty surrounding CBD products remains a challenge for the industry. Tauriga Sciences competes with both established pharmaceutical companies and smaller, specialized CBD brands. The company's success depends on its ability to differentiate its products, build brand awareness, and navigate the evolving regulatory landscape.
Who Are TAUG's Key Customers?
- Consumers seeking CBD-infused products for wellness and health benefits.
- Retailers and distributors who sell CBD products to consumers.
- Wholesale partners who distribute products to various channels.
F-Score 2/9Financial Health
Tauriga Sciences, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
TAUG Valuation & Market Position
With a 3K market cap, Tauriga Sciences, Inc. sits in the micro-cap segment of the market. Relative to its peer group, TAUG's quantitative score of 58/100 is roughly in line with the peer average of 66/100.
Company Profile
Tauriga Sciences, Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Wappingers Falls, US. The company is led by CEO Seth M. Shaw. TAUG has traded publicly since 2002.
TAUG Financials
Bull Case vs Bear Case
Bull Case
- Tauriga's recent insider buying suggests confidence from within, mirroring situations like company executives loading up on shares before positive announcements. The community buzz seems optimistic about upcoming product launches, similar to the anticipation surrounding Apple product releases. There's growing excitement about Tauriga potentially entering new markets, reminiscent of when Tesla expanded into China. Overall, the prevailing sentiment is that Tauriga is undervalued, akin to early perceptions of companies like Amazon before their explosive growth.
- Enthusiasm around new product lines is building up a strong community following.
- The company's focus on innovative products in the health and wellness sector is attracting attention.
- Positive sentiment is increasing due to strategic partnerships.
Bear Case
- Recent community discussions highlight concerns about Tauriga's ability to scale production effectively, similar to challenges faced by smaller biotech firms. Some investors are worried about increased competition in the cannabis-infused product market, comparable to the crowded electric vehicle space. There's skepticism regarding the long-term sustainability of Tauriga's current business model, echoing doubts about companies reliant on single product lines. Concerns exist about the company's marketing strategy and brand visibility, similar to issues faced by companies struggling to differentiate themselves in crowded markets.
- The small size of the company makes it vulnerable to market fluctuations.
- There are some concerns about the company's ability to compete with larger players.
- Negative social media sentiment has emerged due to recent marketing campaigns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · April 2026
TAUG Latest News
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
TAUG Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TAUG.
Price Targets
Wall Street price target analysis for TAUG.
TAUG MoonshotScore
What does this score mean?
The MoonshotScore rates TAUG's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Seth M. Shaw
CEO
Seth M. Shaw serves as the Chief Executive Officer of Tauriga Sciences, Inc. His background includes experience in managing small teams, as evidenced by his current role overseeing just two employees. Information regarding his prior career history, educational background, and specific credentials is not available in the provided data.
Track Record: Due to the limited information available, it is difficult to assess Seth M. Shaw's track record at Tauriga Sciences. The company's current financial performance, characterized by a negative profit margin, suggests that significant challenges remain. His leadership during the collaboration with Aegea Biotechnologies for COVID-19 test development is a notable strategic decision.
TAUG OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Tauriga Sciences may not meet the minimum financial standards or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may be subject to less regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. This tier is also known as the Pink Open Market. Investors should be aware that companies in this tier may carry higher risks due to limited information and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing due to lack of transparency.
- Low trading volume and liquidity can lead to price volatility and difficulty in executing trades.
- Potential for fraud or manipulation is higher on the OTC Other tier compared to major exchanges.
- OTC stocks may be difficult to sell due to limited market interest.
- The company may not meet the listing requirements of major exchanges, indicating potential financial or operational challenges.
- Verify the availability and accuracy of financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Research the company's regulatory compliance and legal history.
- Understand the risks associated with investing in OTC stocks.
- Check for any red flags or warning signs, such as frequent stock dilutions or reverse mergers.
- Consult with a financial advisor before making any investment decisions.
- Collaboration agreement with Aegea Biotechnologies suggests some level of operational activity.
- The company has been in business since 2001, indicating some level of staying power.
- The company has a portfolio of CBD-infused products, including Tauri-Gum.
- The company has a website and e-commerce platform, suggesting some effort to engage with customers.
- The company is headquartered in Wappingers Falls, New York, which is a real physical location.
Tauriga Sciences, Inc. Healthcare Stock: Key Questions Answered
What does Tauriga Sciences, Inc. do?
Tauriga Sciences, Inc. is a specialty drug manufacturer focused on developing and marketing cannabidiol (CBD) infused products. Their flagship product is Tauri-Gum, a CBD-infused chewing gum. The company also offers a range of other CBD-based products, including skincare items, dietary supplements, and bath bombs. Tauriga Sciences distributes its products through e-commerce, distributors, and wholesale channels, targeting consumers seeking the potential wellness benefits of CBD. The company also has a collaboration agreement with Aegea Biotechnologies, Inc. to develop a rapid COVID-19 test.
What do analysts say about TAUG stock?
There is currently no available analyst coverage for Tauriga Sciences (TAUG) stock. Given its OTC listing and small market capitalization, the company may not attract significant attention from institutional analysts. Investors should conduct their own thorough research and due diligence before investing in TAUG, considering the company's financial position, competitive landscape, and regulatory risks. The absence of analyst coverage increases the risk and uncertainty associated with investing in this stock.
What are the main risks for TAUG?
Tauriga Sciences faces several key risks, including intense competition in the CBD market, regulatory uncertainty surrounding CBD products, and its negative profit margin. The company's small size and limited financial resources also pose challenges to its ability to compete with larger players. Furthermore, its reliance on the OTC market increases the risk of low liquidity and potential price volatility. Investors should carefully consider these risks before investing in TAUG.
How does Tauriga Sciences, Inc. navigate regulatory approval processes?
As a company focused on CBD-infused products, Tauriga Sciences operates in a complex and evolving regulatory landscape. The FDA's stance on CBD products remains somewhat unclear, and regulations vary significantly by state and jurisdiction. Tauriga Sciences must ensure that its products comply with all applicable regulations regarding manufacturing, labeling, and marketing. The company's collaboration with Aegea Biotechnologies for a COVID-19 test may also involve navigating regulatory approval processes for medical devices. The company's ability to navigate these regulatory hurdles will be critical to its long-term success.
What is Tauriga Sciences, Inc.'s drug pipeline status?
Tauriga Sciences, Inc. primarily focuses on CBD-infused products rather than traditional pharmaceuticals. Therefore, it does not have a conventional drug pipeline in the same sense as a pharmaceutical company developing novel drug candidates. However, the company is developing anti-nausea products. The company's collaboration with Aegea Biotechnologies to develop a rapid COVID-19 test represents a potential near-term catalyst, but the long-term impact on the company's revenue and profitability remains uncertain. Investors should monitor the progress of this collaboration and any other product development initiatives.
What are the key factors to evaluate for TAUG?
Tauriga Sciences, Inc. (TAUG) holds an AI score of 58/100 (moderate). Not financial advice.
How frequently does TAUG data refresh on this page?
TAUG prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven TAUG's recent stock price performance?
Tauriga Sciences, Inc. (TAUG) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: CBD-infused product line with Tauri-Gum as a flagship product. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may not be complete.
- OTC market investments carry higher risks.
- Financial data is limited and may not be up-to-date.